ΔΕΛΤΙΟ ΤΥΠΟΥ ΔΕΛΤΙΟ ΤΥΠΟΥ

Key Financial Results for the Nine-Month Period 2026

12.5% Increase in Adjusted EBITDA from continuing operations

Peania, November 19, 2026 – Lavipharm S.A. informs the investment community of its key consolidated financial results for the nine-month period of 2026.

The Group's adjusted earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) from continuing operations for the first nine months of 2026 increased by 12.5%, amounting to €10.71 million compared to €9.52 million during the corresponding period of the previous year. Adjusted EBITDA from continuing and discontinued operations amounted to €10.71 million, compared to €10.47 million, posting an increase of 2.3%. It is noted that the previous year's EBITDA included a gain of €0.94 million from the sale of the pharmacy network.

Consolidated Sales before Clawback & Rebates amounted to €61.10 million, compared to €47.74 million during the corresponding period of the previous year, reflecting an increase of 28%.

Gross profit for the first nine months of 2026 stood to €23.59 million, compared to €18.81 million during the corresponding period of 2025, posting an increase of 25.4%. Total net profits after tax from continuing and discontinued operations rose to €4.02 million, from €3.51 million in the first nine months of 2025, posting an increase of 14.3%.

Net debt of the Lavipharm Group on 30/09/2026 stood at €38.04 million.

In relation to sales, exports posted an increase of 36.4%. In the domestic market, prescription drug sales increased by 30% and over-the-counter (OTC) products by 2.1%.

Outlook for Q4 2026

Strong sales growth is expected to continue in the last quarter of the year, both in domestic prescription drugs and in exports. Export activity now also includes sales of the pharmaceutical product DUROGESIC®, which commenced in France on 30/09/2026 and are expanding into additional countries as marketing authorizations continue to be secured at a rapid pace.

KEY CONSOLIDATED FINANCIAL RESULTS BASED ON STATEMENT OF COMPREHENSIVE INCOME

(values in million Euro)	9-month 2026	9-month 2025	Movement %
Sales before Clawback & Rebates from continuing operations	**61.10**	**47.74**	**28.0%**
Clawback & Rebates	**6.01**	**6.13**	**(2.0%)**
Net Sales	**55.09**	**41.61**	**32.4%**
Gross Profit	**23.59**	**18.81**	**25.4%**
Adjusted Earnings before Interest, Taxes, Depreciation, Amortization and Investment Results (EBITDA) from continuing operations	**10.71**	**9.52**	**12.5%**
Adjusted Earnings before Interest, Taxes, Depreciation, Amortisation and Investment Results (EBITDA) from continuing and discontinued operations	**10.71**	**10.47**	**2.3%**
Earnings before Interest and Taxes (EBIT) from continuing operations	**6.79**	**5.73**	**18.6%**
Earnings before Tax from continuing operations	**5.29**	**4.33**	**22.0%**
Net profit for the period from continuing operations	**4.02**	**2.57**	**56.1%**
Earnings from discontinued operations		**0.94**	
Earnings after Tax from continuing and discontinued operations	**4.02**	**3.51**	**14.3%**

GROUP SALES ANALYSIS BY CATEGORY

(values in million Euro)	9-month 2026	9-month 2025	Movement %
Prescription pharmaceuticals domestic sales	35.35	27.18	30.0%
OTC sales	6.93	6.79	2.1%
Pharmaceutical exports	18.63	13.66	36.4%
Other sales	0.19	0.11	75.2%
Total sales	**61.10**	**47.74**	**28.0%**

For further information:

Investor Relations
Vassilis Baloumis
Tel. +30 210 6691 121
ir@lavipharm.com

Corporate Communications
Katerina Papakonstantinou
Tel. +30 210 6691 404
kpapakonstantinou@lavipharm.com

About Lavipharm
Lavipharm (ASE: LAVI) is a pharmaceutical company focused on developing and delivering innovative healthcare solutions that advance patient care. Founded in Greece in 1911 and listed on the Athens Stock Exchange since 1995, the company has a strong presence in prescription and over-the-counter medicines in its domestic market. Lavipharm is internationally recognized for its expertise in transdermal drug delivery systems (TDDS) and maintains a global footprint through products distributed worldwide. With more than 115 years of history, Lavipharm remains committed to helping people live longer, healthier lives.